Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2021-07-27 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
This is to inform you that the Board of Directors of the Company, in their meeting held on Tuesday, 27th July, 2021 (commenced at 09:30 AM and concluded at 11:30 AM), have, inter-alia, ....
Regulatory Filings
2021-07-27 English
This is to inform you that the Board of Directors of the Company, in their meeting held on Tuesday, 27th July, 2021 (commenced at 09:30 AM and concluded at 11:30 AM), have, inter-alia, ....
Interim / Quarterly Report Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the outcome of a Board of Directors meeting held on 27th July 2021. It announces the approval of unaudited standalone and consolidated financial results for the quarter ended 30th June 2021, pursuant to SEBI regulations. The document includes detailed financial data for the quarter, such as revenue, expenses, profit before tax, tax expense, net profit, and earnings per share. It also mentions the inclusion of a Limited Review Report by auditors. The presence of quarterly financial results and the limited review report indicates this is a quarterly financial report rather than a full annual report or just an announcement. The document length (15,000 characters) and detailed financial tables confirm it is a substantive financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2021-07-27 English
Financial Result Updates
Regulatory Filings Classification · 95% confidence The document is a notification from the Board of Directors about the outcome of their meeting held on 27 July 2021. It specifically mentions the approval of unaudited standalone and consolidated financial results for the quarter ended 30 June 2021, pursuant to SEBI regulations. It also states that the results and the Limited Review Report of the auditors are enclosed. The document is short (1799 characters) and serves as an announcement of the financial results and the limited review report, rather than containing the full financial statements or detailed analysis itself. Therefore, it is not the full Interim/Quarterly Report (IR) but an announcement of the results and related documents. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not constitute the full report.
2021-07-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is an intimation to stock exchanges about a scheduled analyst/investor conference call following the declaration of unaudited standalone and consolidated financial results for the quarter ended June 30, 2021 (Q1 FY 2021-22). It includes details about the conference call date, time, access numbers, and participating senior management. The document does not contain the financial results themselves, nor detailed financial statements or analysis. It is a notification about the conference call event related to the quarterly results, not the results or report itself. Therefore, this document is best classified as a Call Transcript (CT) announcement or more precisely an announcement of a conference call. However, since it is only an intimation of the conference call and not the transcript itself, and it is not a full earnings release, the closest fitting category is Call Transcript (CT) as it relates to the conference call event. Confidence is high given the clear mention of the conference call and the absence of actual financial data or report.
2021-07-26 English
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that subsequent to the declaration of unaudited ....
Regulatory Filings Classification · 95% confidence The document is an intimation to stock exchanges about a scheduled analyst/investor conference call following the declaration of unaudited standalone and consolidated financial results for the quarter ended June 30, 2021 (Q1 FY 2021-22). It includes details about the conference call date, time, access numbers, and participating senior management. The document does not contain the financial results themselves, nor detailed financial statements or analysis. It is a notification about the conference call event related to the quarterly results, not the earnings release or the transcript of the call. Therefore, the document is best classified as a Call Transcript (CT) precursor or announcement, but since it is only an intimation of the conference call and not the transcript, it fits best under Regulatory Filings (RNS) as a general regulatory announcement. Confidence is high because the document clearly states it is an intimation of the conference call post results and does not contain the results or transcript itself.
2021-07-26 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the loss of share certificates by shareholders and the request for issuance of duplicate share certificates. It references Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate loss and related disclosures. The content is a notification/intimation about share certificate loss, not a financial report, earnings release, or management discussion. It does not contain financial data or results, nor is it a meeting-related document or voting result. It is a regulatory compliance announcement related to share certificates. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-07-22 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.